Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Valeant Receives Non-Approvable Letter from FDA for Labeling Application of Cannabinoid Cesamet™
- COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has received a non-approvable letter from the U.S. Food and Drug Administration for the company's application requesting labeling changes to its previously approved drug Cesamet CII nabilone. The FDA requested additional information to address concerns over potential class...
- Research articles 2005-12-30
- Life Without Blockbusters: What Valeant's Woes Portend for Pharma
- It's now a truism that the drug industry's "blockbuster model" has pretty much had its day. Much of Big Pharma is having a terrible time winning approval for new drugs and even keeping up sales of existing blockbusters, in part because their underlying rationale -- that pushing drugs into mass...
- Blog posts 2008-05-05
Additional Resources
- Valeant Executive Pay Doubles to $19.7 Million Despite Quadrupling of Company's Losses
- Valeant Pharmaceuticals saw its revenues decline, its net loss quadruple, and its cash sink by $109 million in 2008. But the compensation of its top executives doubled, to $19.7 million in 2008 from $8.6 million in 2007. Half of that, $9.7 million, went to CEO J. Michael...
- Blog posts 2009-03-27
- Valeant Pharmaceuticals Receives Approvable Letter from FDA Regarding Zelapar
- COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that the company received an approvable letter from the U.S. Food and Drug Administration FDA for ZelaparTM selegiline hydrochloride. The approvable letter requests additional clarification on specific issues previously addressed by Valeant. Valeant plans to meet with the FDA, promptly...
- Research articles 2005-10-04
- Valeant Pharmaceuticals Announces Appointment of Timothy C. Tyson as President and Chief Executive Officer
- COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that Timothy C. Tyson was appointed President and Chief Executive Officer of the company on January 1, 2005, in accordance with its previously announced CEO succession plan. Mr. Tyson previously served as Valeant's President and Chief Operating Officer and succeeds...
- Research articles 2005-01-04
- Valeant Pharmaceuticals to Initiate Clinical Development of Viramidine® in Japan; Valeant Forms Hepatitis C Advisory Board in Japan
- COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced plans to initiate the development of ViramidineR in Japan following the first meeting of the company's hepatitis C Japanese advisory board, which was held Monday evening in Tokyo. The company is developing Viramidine, a nucleoside guanosine analog, in oral form...
- Research articles 2005-07-25
- Valeant Pharmaceuticals to Acquire Xcel Pharmaceuticals; Acquisition Expands Valeant's Neurology Franchise in North America; Adds Retigabine to Pipeline
- COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has signed a definitive agreement to acquire Xcel Pharmaceuticals, a privately held specialty pharmaceutical company focused on neurology products in the United States. The transaction significantly expands Valeant's business in North America and enhances the company's neurology franchise...
- Research articles 2005-02-02
- Valeant Pharmaceuticals Agrees to Acquire Rights to Hep-C Drug Infergen® from InterMune
- COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has signed a definitive agreement to acquire the United States and Canadian rights to the hepatitis C drug InfergenR (interferon alfacon-1) from InterMune, Inc. (NASDAQ:ITMN). Valeant will pay InterMune $113.5 million in cash upon closing, and subsequent milestone...
- Research articles 2005-11-28
- Valeant Pharmaceuticals Announces Results of Caleel + Hayden Lawsuit
- COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that the jury in its lawsuit with Caleel + Hayden, LLC returned a verdict against the company in Orange County Superior Court and awarded Caleel + Hayden damages in the amount of $2.4 million in a dispute regarding Valeant's termination...
- Research articles 2006-07-11
- Valeant Pharmaceuticals Sells Hep-C Drug Infergen® to Three Rivers Pharmaceuticals®, LLC for $91 Million
- ALISO VIEJO, Calif. & CRANBERRY TOWNSHIP, Pa. -- Valeant Pharmaceuticals International (NYSE:VRX) and Three Rivers Pharmaceuticals, LLC jointly announced today that they have signed a definitive agreement for Valeant to divest the United States and Canadian rights to the hepatitis C drug Infergen (interferon alfacon-1) to Three Rivers. Valeant will...
- Research articles 2007-12-20
- Valeant Pharmaceuticals Settles Galenika Dispute; New Serbian Government Key to Resolution
- COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has reached an agreement to resolve its long-standing dispute with the Health Fund of Serbia and the Republic of Serbia regarding their joint venture, Galenika. Under the agreement, Valeant collected $28 million of a total of $34 million...
- Research articles 2006-03-08
- Valeant Pharmaceuticals to Present at Merrill Lynch Pharmaceutical, Biotechnology and Medical Device Conference
- COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE: VRX) announced today that Valeant's senior management team will be presenting at the Merrill Lynch Global Pharmaceuticals, Biotechnology & Medical Device Conference on Tuesday, February 8, 2005 at 8:00 a.m. Eastern Time. The conference will be held at the Grand Hyatt New...
- Research articles 2005-02-04
- Valeant Pharmaceuticals Makes a Strong Showing at the Movement Disorder Society's 9th International Congress
- COSTA MESA, Calif. -- Global Tasmar Launch and Recent Acquisition of Xcel Pharmaceuticals Demonstrate Valeant's Dedication to Neurosciences Valeant Pharmaceuticals International (NYSE:VRX) is advancing its commitment to the company's neurosciences business with a strong presence at The Movement Disorder Society's 9th International Congress of Parkinson's Disease and Movement Disorders,...
- Research articles 2005-03-05
- Valeant's Six New Value Aligned Pay Practices
- Value Expectations submits: By David Lee Berkowitz Valeant CEO's Pay Package Draws Praise as a Model - WSJ.com. In the above article in Wednesday's WSJ, G Mason Morfit, chairman of Valeant's VRX board compensation committee and a partner at ValueAct, an activist hedge...
- External links 2009-09-03
- Valeant Pharmaceuticals to Partner with ASCEND Therapeutics to Promote Migranal® to OB/GYNs
- ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has granted ASCEND Therapeutics exclusive rights to deploy ASCEND's 50-person specialty sales force to promote Valeant's Migranal([R])(dihydroergotamine mesylate, USP) Nasal Spray to more than 5,500 OB/GYNs in the United States. Valeant will continue to market Migranal to physicians...
- Research articles 2007-10-01
- Valeant Pharmaceuticals to Initiate Retigabine Phase 3 Clinical Trials; Retigabine Represents the First in a New Class of Epilepsy Treatments; First of Two Phase 3 Studies to Initiate Enrollment in Third Quarter of 2005
- COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it intends to initiate enrollment in the third quarter of 2005, for a Phase 3 trial for retigabine, which is being developed as an adjunctive treatment for partial-onset seizures in patients with epilepsy. The trial is one of two...
- Research articles 2005-07-26
- Valeant Pharmaceuticals Appoints PAREXEL to Assist with Retigabine Regulatory Applications
- ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) announced today that it has appointed PAREXEL International Corp. to develop, coordinate and prepare the New Drug Application NDA and the European Marketing Authorization Application MAA for Valeant's investigational compound retigabine. Retigabine is a novel neuronal potassium-channel opener that is being studied...
- Research articles 2007-05-29
- Valeant Pharmaceuticals Submits Complete Response to FDA Approvable Letter for Zelapar
- COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that it has recently submitted a complete response to an approvable letter from the U.S. Food and Drug Administration FDA for ZelaparR selegiline following the successful completion of two safety studies required for Zelapar's approval. Valeant expects the FDA...
- Research articles 2005-01-05
- Q4 2005 Valeant Pharmaceuticals International Earnings Conference Call - Research and Markets Offers a Brief of 'Valeant Pharmaceuticals International' Conference Call
- DUBLIN, Ireland -- The Valeant Pharmaceuticals International (NYSE:VRX) Corporate Conference Call took place on 28-Feb-06 9:00am ET.
- Research articles 2006-02-28
- Valeant Pharmaceuticals to Initiate Study of Retigabine for Pain Associated with Post-Herpetic Neuralgia
- ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) announced today that it will initiate a clinical trial with retigabine in the treatment of pain associated with post-herpetic neuralgia PHN. Valeant filed an Investigational New Drug IND application with the U.S. Food and Drug Administration FDA and following FDA review, the...
- Research articles 2007-05-31
- << Previous
- page 1 of 1
- Next >>
Presented by American Express